Natco Pharma Ltd.

Natco Pharma has informed that the Board of Directors at their meeting held today, September 25, 2025, has given their in-principle approval to evaluate the demerger of the Agro business of the Company into a separate entity. The management believes that this move shall enable value unlocking of the core business (pharmaceuticals) and enhance long-term growth. Further, it also provides operational flexibility, focused and dedicated management (for respective businesses), different brand positioning for each legal entity. As a part of the proposed reorganization, the Company may retain a small minority stake in the resulting company. This is to support the company in terms of common services such as R&D, Patents, etc. Support via Transitional Service Agreements (TSAs) at arm’s length pricing. Board has authorized the management to undertake detailed evaluation of the proposed demerger suggesting optimal capital & shareholding structure as indicated above and present to the Audit Committee and Board of Directors.

The above information is a part of company’s filings submitted to BSE.